Infliximab- and methotrexate-resistant rebound of psoriasis after discontinuation of efalizumab (Raptiva®) [5]

British Journal of Dermatology

Volumn 155, Issue 4, 2006, Pages 846-847

  Thielen, A M ^a   Barde, C ^a   Saurat, J H ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE DIPROPIONATE; CALCIPOTRIOL; EFALIZUMAB; INFLIXIMAB; METHOTREXATE; VITAMIN D DERIVATIVE;

ADULT; CASE REPORT; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; ERYTHRODERMA; FEVER; HUMAN; LEG EDEMA; LETTER; MALE; PRIORITY JOURNAL; PSORIASIS; SCORING SYSTEM; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; DERMATOLOGIC AGENTS; DRUG RESISTANCE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; PSORIASIS; RECURRENCE;

EID: 33748445896     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2006.07447.x     Document Type: Letter

References (4)

1. Thielen AM, Kuenzli S, Saurat JH. Cutaneous adverse events of biological therapy for psoriasis: review of the literature. Dermatology 2005; 211:207-15.
2. Leonardi CL. Efalizumab in the treatment of psoriasis. Dermatol Ther 2004; 17:393-400.
3. Dumont-Berset M, Laffitte E, Gerber C et al. Eczematous drug eruption after infliximab. Br J Dermatol 2004; 151:1272-3.
4. Wright RC. Atopic dermatitis-like eruption precipitated by infliximab. J Am Acad Dermatol 2003; 49:160-1.